{
    "clinical_study": {
        "@rank": "68907", 
        "arm_group": [
            {
                "arm_group_label": "3% hypertonic saline group", 
                "arm_group_type": "Experimental", 
                "description": "Once consented, the study drug (in this arm: 3% Hypertonic Saline) will be ordered by a physician at the request of a study team member. Once the drug order set is received by a pharmacist, he/she will obtain the study drug from an Omnicell and prepare the medication to a volume of 3 mL in a syringe with a blinded study label prepared in advance by the IDS pharmacy.  The pharmacist will then give the study drug to the patient's respiratory therapist or the bedside nurse. The respiratory therapist or the nurse will pour the drug from a syringe to an inhaler cup and the study drug will be given by the standard nebulizer over the course of  15 minutes."
            }, 
            {
                "arm_group_label": "0.9% normal saline group", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Once consented, the study drug (in this arm: 0.9% normal saline) will be ordered by a physician at the request of a study team member. Once the drug order set is received by a pharmacist, he/she will obtain the study drug from an Omnicell and prepare the medication to a volume of 3 mL in a syringe with a blinded study label prepared in advance by the IDS pharmacy.  The pharmacist will then give the study drug to the patient's respiratory therapist or the bedside nurse. The respiratory therapist or the nurse will pour the drug from a syringe to an inhaler cup and the study drug will be given by the standard nebulizer over the course of  15 minutes."
            }
        ], 
        "brief_summary": {
            "textblock": "This is a randomized, double-blind, controlled trial  in the Pediatric Emergency Department.\n      The primary objective is to determine whether nebulized 3% hypertonic saline is more\n      effective than nebulized 0.9% saline in the treatment of bronchiolitis in the emergency\n      department."
        }, 
        "brief_title": "Nebulized 3% Hypertonic Saline in the Treatment of Acute Bronchiolitis", 
        "condition": "Acute Bronchiolitis", 
        "condition_browse": {
            "mesh_term": "Bronchiolitis"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Children 2-12 months of age presenting to Emergency Department\n\n          -  Patients with a diagnosis of bronchiolitis defined as the first episode of wheezing\n             and/or crackles in a child younger than 12 months who has physical findings of a\n             viral respiratory infection and has no other explanation for the wheezing and/or\n             crackles\n\n          -  Patients with an RDAI score \u2265 6 as measured by a trained respiratory therapist\n\n        Exclusion Criteria:\n\n          -  Previous history of wheezing\n\n          -  Known heart or lung disease\n\n          -  Premature birth defined as birth before 37 weeks gestation\n\n          -  Immunosuppression or immunodeficiency\n\n          -  Treatment with corticosteroids in the previous 48 hours\n\n          -  Critically ill children - progressive respiratory failure requiring higher level of\n             care, vital signs instability/need for emergency interventions to prevent clinical\n             deterioration\n\n          -  Oxygen saturation <85% on room air at the time of recruitment"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "12 Months", 
            "minimum_age": "2 Months"
        }, 
        "enrollment": {
            "#text": "60", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "January 3, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02029040", 
            "org_study_id": "STU 012013-040"
        }, 
        "intervention": {
            "arm_group_label": [
                "3% hypertonic saline group", 
                "0.9% normal saline group"
            ], 
            "description": "Within 5-15 minutes following the administration of the study drug, the Respiratory Distress Assessment Instrument (RDAI) score will be reassessed and study interventions are complete. The patient will be observed for one hour in the emergency department (ED). However, further treatments may be started immediately upon discretion of the treating physician. If the patient is discharged home study PI and/or research assistant will call the parents 7 days from the ED visit to check the number of visits to their primary doctor and/or EDs due to same illness.", 
            "intervention_name": "3% Hypertonic Saline versus 0.9 % normal saline", 
            "intervention_type": "Drug"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Bronchiolitis", 
            "Hypertonic saline", 
            "Emergency Department"
        ], 
        "lastchanged_date": "January 7, 2014", 
        "location": {
            "contact": {
                "email": "Mohamed.Badawy@utsouthwestern.edu", 
                "last_name": "Mohamed Badawy, MD", 
                "phone": "214-456-7106"
            }, 
            "facility": {
                "address": {
                    "city": "Dallas", 
                    "country": "United States", 
                    "state": "Texas", 
                    "zip": "75235"
                }, 
                "name": "UT Southwestern Medical Center; Children's Medical Center"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Randomized Trial of Nebulized 3% Hypertonic Saline in the Treatment of Acute Bronchiolitis in The Emergency Department", 
        "overall_contact": {
            "email": "Mohamed.Badawy@utsouthwestern.edu", 
            "last_name": "Mohamed Badawy, MD", 
            "phone": "214-456-7106"
        }, 
        "overall_contact_backup": {
            "email": "Kresimir.Aralica@utsouthwestern.edu", 
            "last_name": "Kresimir Aralica, MD", 
            "phone": "214-456-6371"
        }, 
        "overall_official": {
            "affiliation": "UT Southwestern Medical Center", 
            "last_name": "Mohamed Badawy, MD", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The primary outcome variable is the Respiratory Assessment Change Score (RACS) which is a sum of the change in the Respiratory Distress Assessment Instrument (RDAI)score plus a standardized score for the change in respiratory rate; the change in respiratory rate is assigned 1 point per each 10% change in the respiratory rate", 
            "measure": "Respiratory Assessment Change Score (RACS)", 
            "safety_issue": "No", 
            "time_frame": "15 minutes; one hour"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02029040"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Rate of Hospitalizations", 
                "safety_issue": "No", 
                "time_frame": "24 hours"
            }, 
            {
                "measure": "Return to Emergency Department", 
                "safety_issue": "No", 
                "time_frame": "7 days"
            }
        ], 
        "source": "University of Texas Southwestern Medical Center", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "University of Texas Southwestern Medical Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "December 2013", 
        "study_design": "Allocation: Randomized, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "January 2014"
    }
}